Literature DB >> 17396141

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Mitch Dowsett1, Wedad M Hanna, Mark Kockx, Frederique Penault-Llorca, Josef Rüschoff, Thorsten Gutjahr, Kai Habben, Marc J van de Vijver.   

Abstract

Human epidermal growth factor receptor 2 (HER2) positivity in breast cancer is a prognostic factor regarding tumor aggressiveness and a predictive factor for response to trastuzumab (Herceptin). Early and accurate HER2 testing of all breast cancer patients at primary diagnosis is essential for optimal disease management. Routine HER2 tests, such as immunohistochemistry and fluorescence in situ hybridization (FISH), are subject to interlaboratory variation, and validation by laboratory proficiency testing is important to improve standardization. This study compared immunohistochemistry and FISH testing between five international pathology reference centers. Each center evaluated 20 immunohistochemistry and 20 FISH breast cancer specimens in five testing rounds. In each round, one center selected two sets of four different invasive tumor specimens (set A for immunohistochemistry and set B for FISH) and sent samples to the other four centers in a blinded manner, while retaining samples for its own evaluation. Results were analyzed by an independent coordinator. With immunohistochemistry, there were no differences between the five centers for any of the specimens at the level of diagnostic decision (positive or negative HER2 status). However, differences between laboratories were observed in immunohistochemistry scoring. Of the 20 specimens, four were scored as negative (0/1+) and five as positive (3+) in all centers; eight were negative or equivocal (2+), and three positive or equivocal. After FISH retesting of nine of the 11 equivocal immunohistochemistry cases, consensus was achieved in 15 of 18 (83%) specimens. FISH analysis of set B specimens resulted in consensus between centers in 16 of 20 (80%) specimens (six negative and 10 positive). All four discordant FISH specimens were scored as having HER2:CEP17 ratios within the range 1.7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396141     DOI: 10.1038/modpathol.3800774

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  45 in total

1.  A Root Cause Analysis Into the High Error Rate in Clinical Immunohistochemistry.

Authors:  Steven A Bogen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-02-22

Review 2.  Antibody validation.

Authors:  Jennifer Bordeaux; Allison Welsh; Seema Agarwal; Elizabeth Killiam; Maria Baquero; Jason Hanna; Valsamo Anagnostou; David Rimm
Journal:  Biotechniques       Date:  2010-03       Impact factor: 1.993

Review 3.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

Review 4.  Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains.

Authors:  Halliday A Idikio
Journal:  Int J Clin Exp Pathol       Date:  2009-11-25

Review 5.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

6.  Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations.

Authors:  Sharenda L Williams; George G Birdsong; Cynthia Cohen; Momin T Siddiqui
Journal:  Int J Clin Exp Pathol       Date:  2009-01-20

7.  Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.

Authors:  Lynne Dobson; Catherine Conway; Alan Hanley; Alex Johnson; Sean Costello; Anthony O'Grady; Yvonne Connolly; Hilary Magee; Daniel O'Shea; Michael Jeffers; Elaine Kay
Journal:  Histopathology       Date:  2010-06-24       Impact factor: 5.087

8.  Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

Authors:  Jeffrey S Larson; Laurie J Goodman; Yuping Tan; Lisa Defazio-Eli; Agnes C Paquet; Jennifer W Cook; Amber Rivera; Kristi Frankson; Jolly Bose; Lili Chen; Judy Cheung; Yining Shi; Sarah Irwin; Linda D B Kiss; Weidong Huang; Shannon Utter; Thomas Sherwood; Michael Bates; Jodi Weidler; Gordon Parry; John Winslow; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  Patholog Res Int       Date:  2010-06-28

9.  Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Authors:  Shelly Gunn; I-Tien Yeh; Irina Lytvak; Budi Tirtorahardjo; Natasha Dzidic; Soheila Zadeh; Jaeweon Kim; Chris McCaskill; Lony Lim; Mercedes Gorre; Mansoor Mohammed
Journal:  BMC Cancer       Date:  2010-07-28       Impact factor: 4.430

10.  TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.

Authors:  Elisa Rossi; Vincenzo Villanacci; Gabrio Bassotti; Francesco Donato; Andrea Festa; Gianpaolo Cengia; Salvatore Grisanti; Renzo Cestari
Journal:  Histopathology       Date:  2010-06-16       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.